OptiNose — Q1 2020 Earnings Presentation
18 slides from OptiNose's earnings presentation, May 7, 2020
Slide 1: Building a Leading ENT / Allergy Specialty Company
Exhibit 99.2 Building a Leading ENT / Allergy Specialty Company Corporate Presentation May 7, 2020
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for this pu
Slide 3: Key Takeaways and Q1 2020 Highlights
Key Takeaways and Q1 2020 Highlights Adapted Business to the COVID-19 Environment Taking Action to Preserve Strength of Balance Sheet Revising Financial Guidance for Full Year 2020 Commercial Strategy Driving Strong XHANCE Growth Substantial Growth Opportunity Remains for XHANCE +149% $149M Up to XH
Slide 4: COVID-19 Pandemic Response
COVID-19 Pandemic Response optinose_ oR
Slide 5: Overview of COVID-19 Effects on our Business
Overview of COVID-19 Effects on our Business Commercial . Initiated a virtual sales model starting in mid-March and deployed new systems supporting ‘virtualization’ of most commercial efforts . Launched the XHANCE ASSIST program to facilitate product adoption during crisis by physicians and patients
Slide 6: XHANCE Resilience
XHANCE Resilience Prescriptions of XHANCE increased 8% from the 6-weeks ended March 13, 2020 to the 6-weeks ended April 24, 2020 XHANCE TRx (in thousands) 40 +8% . During initial crisis period (6-weeks ending April 24), sales representatives were 30 28.0 required to ‘shelter at home’ and adopt 25.9
Slide 7: XHANCE Launch Update
XHANCE Launch Update optinose_
Slide 8: Q1 2020 XHANCE New and Refill Prescriptions
Q1 2020 XHANCE New and Refill Prescriptions New prescriptions of XHANCE increased Refill prescriptions of XHANCE increased 75% in Q1 2020 compared to Q1 2019 246% in Q1 2020 compared to Q1 2019 XHANCE NRx (in thousands) XHANCE Refills (in thousands) 40 +246% 30 +75% 33.7 22.3 30 20 20 12.7 10 9.8 10
Slide 9: XHANCE Prescription Trends
XHANCE Prescription Trends Prescriptions of XHANCE increased 149% in Q1 2020 compared to Q1 2019 XHANCE Prescriptions (in thousands) 70 +149% 56.1 60 54.3 50 43.0 40 33.9 33.0 33.7 30 25.2 22.5 18.4 20 9.8 22.3 10 17.8 21.2 12.7 15.6 0 Q1 '19 Q2 '19 Q3 '19 Q4 '19 Q1 '20 New Prescriptions Refills TRx
Slide 10: XHANCE Share of INS Prescriptions Within Target Physician Audience
XHANCE Share of INS Prescriptions Within the Target Physician Audience is Growing and the Remaining Opportunity is Large Market share within the XHANCE target physician audience of 3.8% in Q1 2020 an increase of 2.5 times compared to Q1 2019 share of 1.5% XHANCE Share of INS TRx Within Target Physic
Slide 11: Number of XHANCE Prescribers by Prescribing Frequency
Number of XHANCE Prescribers by Prescribing Frequency Physicians who had more than 15 XHANCE prescriptions filled by their patients in a quarter increased by 211% from Q1 2019 to Q1 2020 (895 versus 288) XHANCE Prescribers 7,000 6,345 5,859 6,000 895 5,075 828 5,000 3, 706 4,442 665 1,506 1,599 4,00
Slide 12: Q4 2019 Financial Update
Q4 2019 Financial Update optinose_
Slide 13: Financial Review – First Quarter 2020
Financial Review – First Quarter 2020 Q1 2020 XHANCE Net Revenue Increased 78% Compared to Q1 2019 ($M ) XHANCE Net Revenue +78% XHANCE Average Net Revenue per TRx $7.1 . XHANCE average net revenue of $126 per TRx in Q1 2020 $4.0 • Expectation was $120 – $140 for Q1 2020 Q1 '19 Q1 '20 13
Slide 14: Corporate Guidance Update
Corporate Guidance Update . XHANCE Net Revenue and Average Net Revenue per TRx . Withdrawing FY 2020 revenue guidance given uncertainties related to the COVID-19 pandemic . XHANCE Average Net Revenue per Prescription expected to improve substantially for the remainder of 2020 . Operating Expense (GA
Slide 15: Closing Remarks
Closing Remarks optinose_
Slide 16: Key Takeaways and Q1 2020 Highlights
Key Takeaways and Q1 2020 Highlights Adapted Business to the COVID-19 Environment Taking Action to Preserve Strength of Balance Sheet Revising Financial Guidance for Full Year 2020 Commercial Strategy Driving Strong XHANCE Growth Substantial Growth Opportunity Remains for XHANCE +149% $149M Up to XH
Slide 17: Investor Relations
Investor Relations – NASDAQ: OPTN At 31 March 2020: Analyst Coverage 1 – $149 million in cash – Long-term debt: $110 million BMO: Gary Nachman – 45.9 million common shares o/s – 11.1 million options & warrants o/s Cantor Fitzgerald: Brandon Folkes Cowen: Ken Cacciatore Optinose Investor Contact Jeff
Slide 18: Building a Leading ENT / Allergy Specialty Company
Building a Leading ENT / Allergy Specialty Company Corporate Presentation May 7, 2020